LAMP2A regulates cisplatin resistance in colorectal cancer through mediating autophagy
Authors:
Open Access
- 8 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (5) , 1-12
Abstract
Background: Drug resistance is an important constraint on clinical outcomes in advanced cancers. LAMP2A is a limiting protein in molecular chaperone-mediated autophagy. This study was aimed to explore LAMP2A function in cisplatin (cis-diamminedichloroplatinum, DDP) resistance colorectal cancer (CRC) to seek new ideas for CRC clinical treatment. Methods: In this study, LAMP2A expression was analyzed by molecular experimental techniques,such as qRT-PCR and western blot. Then, LAMP2A in cells was interfered by cell transfection experiments. Subsequently, the function of LAMP2A on proliferation, migration, invasion, DDP sensitivity, and autophagy of CRC/DDP cells were further investigated by a series of experiments, such as CCK-8, transwell, and western blot. Results: We revealed that LAMP2A was clearly augmented in DDP-resistant CRC and was related to poor patient prognosis. Functionally, LAMP2A insertion remarkably CRC/DDP proliferation, migration, invasion ability and DDP resistance by strengthen autophagy. In contrast, LAMP2A knockdown limited the proliferation, migration, and invasion while heightened cellular sensitivity to DDP by restraining autophagy in CRC/DDP cells. Furthermore, LAMP2A silencing was able to curb tumor formation and enhance sensitivity to DDP in vivo. Conclusion: In summary, LAMP2A boosted malignant progression and DDP resistance in CRC/DDP cells through mediating autophagy. Clarifying LAMP2A function in DDP resistance is promising to seek cancer therapies biomarkers targeting LAMP2A activity.Keywords
All Related Versions
Funding Information
- Guiding project of Jiangsu Provincial Health Commission (Z2021032, Z2021032, Z2021032, Z2021032, Z2021032, Z2021032, Z2021032)
- Key Laboratory of New Drug Research and Clinical Pharmacy in Jiangsu Province (XZSYSKF2020027, XZSYSKF2020027, XZSYSKF2020027, XZSYSKF2020027, XZSYSKF2020027, XZSYSKF2020027, XZSYSKF2020027)
- Suzhou Medical and Health Science and Technology Innovation Project (SKY2021020, SKY2021020, SKY2021020, SKY2021020, SKY2021020, SKY2021020, SKY2021020)
- Changshu City Science and Technology Development Plan (CS202125, CS202125, CS202125, CS202125, CS202125, CS202125, CS202125)
- Suzhou City clinical key disease diagnosis and treatment technology special project (LCZX202224, LCZX202224, LCZX202224, LCZX202224, LCZX202224, LCZX202224, LCZX202224)
This publication has 43 references indexed in Scilit:
- Chaperone-mediated autophagy regulates proliferation by targeting RND3 in gastric cancerAutophagy, 2016
- Chaperone-mediated autophagy prevents apoptosis by degrading BBC3/PUMAAutophagy, 2015
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatmentCell Death & Disease, 2013
- Chaperone-Mediated Autophagy Is Required for Tumor GrowthScience Translational Medicine, 2011
- Autophagy: cellular and molecular mechanismsThe Journal of Pathology, 2010
- The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal MembraneMolecular and Cellular Biology, 2008
- How to Interpret LC3 ImmunoblottingAutophagy, 2007
- Activation of Chaperone-mediated Autophagy during Oxidative StressMolecular Biology of the Cell, 2004
- Regulation of Lamp2a Levels in the Lysosomal MembraneTraffic, 2000